September 6, 2005
Stephen M. Hahn, MD, Named Chair
Radiation Oncology at the University of Pennsylvania
School of Medicine
(Philadelphia, PA) — Stephen M. Hahn,
MD, has been named the new Chair and Henry
K. Pancoast Professor of Radiation Oncology at the University
of Pennsylvania School of Medicine.
As a radiation and medical oncologist, as well as an
NIH-funded researcher, Dr. Hahn brings his many skills
and talents to lead one of the nation’s foremost
academic radiation oncology departments. He is an active
clinician, with particular expertise in treating lung
and genitourinary cancers and in the use of photodynamic
therapy. As Vice Chair for Research for the Department
of Radiation Oncology and Principal Investigator of
National Cancer Institute grants, Hahn has led the expansion
of the department’s research base, which has consistently
ranked first or second in NIH funding.
“Dr. Hahn was selected for this position because
of his reputation for excellence as a superb clinician
and researcher, his highly collaborative and dynamic
leadership style, and his vision for the department,”
says Arthur H. Rubenstein, MBBCH, Executive
Vice President of the University of Pennsylvania for
the Health System and Dean of the School of Medicine.
“On a personal level, he is highly regarded by
colleagues, patients, and students as a gifted scientist,
compassionate master physician, and an exceptional educator,
communicator, and role model.”
Prior to joining Penn in 1996, Hahn was a Medical and
Radiation Oncologist in Santa Rosa, CA. From 1993-95,
he served as Chief of the National Cancer Institute’s
Prostate Cancer Clinic, Clinical Pharmacology Branch,
in Bethesda, MD, and a senior investigator at the NCI.
Hahn also served as a Commander in the NCI’s U.S.
Public Health Service from 1989-95.
After joining Penn in 1996, Hahn served as an Assistant
Professor of Radiation Oncology and Hematology/Oncology
until 2001, when he was appointed Associate Professor.
For the past several years, Hahn has served as Director
of Penn’s Photodynamic Therapy program, which
treats cancer patients through a minimally invasive
process that uses a photosensitizer and concurrent laser
light to selectively destroy tumors. He also directs
the Farnesyltransferase Inhibitor Program for Treatment
of cancer of the lung, head and neck and pancreas. In
addition, Hahn is the Program Leader of the Radiation
Biology Research Program in the Abramson Cancer
Center of the University of Pennsylvania, and
was recently appointed to the Cancer Center’s
Board certified in Internal Medicine, Radiation Oncology,
and Hematology/Oncology, Hahn received his medical degree
from Temple University School of Medicine and his undergraduate
degrees from Rice University. In 1987, he completed
his residency and served as Chief Resident of Internal
Medicine at the University of California, San Francisco.
Hahn also completed a Medical Oncology Fellowship at
the NCI in 1991, and a Radiation Oncology Residency
at the NCI in 1994.
Hahn currently serves as Associate Chair for the Annual
Meeting and Program Committee of the American Society
of Therapeutic Radiology and Oncology, and as Sub-Committee
Chair for the ASTRO Annual Meeting-Scientific Program.
A long-standing member of the American Society of Clinical
Oncology, Hahn is also an active member of the Radiation
Research Society, the American Society of Photobiology,
the American Association for Cancer Research, and the
University of Pennsylvania’s John Morgan Society.
Hahn resides in Glen Mills, PA, with his wife, Lotta,
and their four children.
a printer friendly version of this release,
PENN Medicine is a $2.7 billion
enterprise dedicated to the related missions of medical
education, biomedical research, and high-quality patient
care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation's
first medical school) and the University of Pennsylvania
Penn’s School of Medicine is ranked #2 in
the nation for receipt of NIH research funds; and ranked
#4 in the nation in U.S. News & World Report’s
most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its
superior education and training of the next generation
of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes:
its flagship hospital, the Hospital of the University
of Pennsylvania, consistently rated one of the nation’s
“Honor Roll” hospitals by U.S. News &
World Report; Pennsylvania Hospital, the nation's first
hospital; Penn Presbyterian Medical Center; a faculty
practice plan; a primary-care provider network; two
multispecialty satellite facilities; and home health
care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.